{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:37:15Z","timestamp":1760747835736,"version":"build-2065373602"},"reference-count":8,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ejca.2024.113602","type":"journal-article","created":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T12:38:42Z","timestamp":1707136722000},"page":"113602","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Letter re: Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: A population-based study"],"prefix":"10.1016","volume":"201","author":[{"given":"Marta","family":"Lagan\u00e0","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Cosentini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido Alberto Massimo","family":"Tiberio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Sigala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Berruti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2024.113602_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113424","article-title":"Menke-van der Houven van Oordt CW. Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: a population-based study","volume":"196","author":"Debets","year":"2024","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2024.113602_bib2","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"10.1016\/j.ejca.2024.113602_bib3","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","article-title":"ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Fassnacht","year":"2020","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2024.113602_bib4","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s12020-022-03075-y","article-title":"Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen","volume":"77","author":"Turla","year":"2022","journal-title":"Endocrine"},{"key":"10.1016\/j.ejca.2024.113602_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.669426","article-title":"Cytotoxic effect of progesterone, tamoxifen and their combination in experimental cell models of human adrenocortical cancer","volume":"12","author":"Rossini","year":"2021","journal-title":"Front Endocrinol"},{"issue":"7","key":"10.1016\/j.ejca.2024.113602_bib6","doi-asserted-by":"crossref","first-page":"6829","DOI":"10.3390\/ijms24076829","article-title":"Preclinical evidence of progesterone as a new pharmacological strategy in human adrenocortical carcinoma cell lines","volume":"24","author":"Tamburello","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.ejca.2024.113602_bib7","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s12020-018-1795-x","article-title":"In vitro antitumor activity of progesterone in human adrenocortical carcinoma","volume":"63","author":"Fragni","year":"2019","journal-title":"Endocrine"},{"issue":"18","key":"10.1016\/j.ejca.2024.113602_bib8","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.3390\/cancers15184491","article-title":"Feasibility and activity of megestrol acetate in addition to etoposide, doxorubicin, cisplatin, and mitotane as first-line therapy in patients with metastatic\/unresectable adrenocortical carcinoma with low performance status","volume":"15","author":"Turla","year":"2023","journal-title":"Cancers"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924000789?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924000789?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:43:08Z","timestamp":1760733788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924000789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":8,"alternative-id":["S0959804924000789"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.113602","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Letter re: Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: A population-based study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.113602","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114035","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113424","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113602"}}